Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2004 2
2005 2
2006 2
2008 1
2011 1
2012 3
2013 4
2014 1
2015 3
2016 3
2017 3
2018 7
2019 2
2020 3
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Murine Modeling of Myeloproliferative Neoplasms.
Chen K, Shih AH. Chen K, et al. Among authors: shih ah. Hematol Oncol Clin North Am. 2021 Apr;35(2):253-265. doi: 10.1016/j.hoc.2020.11.007. Epub 2020 Dec 30. Hematol Oncol Clin North Am. 2021. PMID: 33641867 Review.
Molecular biology of myelodysplastic syndromes.
Shih AH, Levine RL. Shih AH, et al. Semin Oncol. 2011 Oct;38(5):613-20. doi: 10.1053/j.seminoncol.2011.04.013. Semin Oncol. 2011. PMID: 21943667 Free PMC article. Review.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL. McKenney AS, et al. Among authors: shih ah. J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22. J Clin Invest. 2018. PMID: 29355841 Free PMC article.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL. McKenney AS, et al. Among authors: shih ah. J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. J Clin Invest. 2018. PMID: 30222137 Free PMC article. No abstract available.
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, Grimes HL, Roboz GJ, Kruger RG, Creasy CL, Paietta EM, Levine RL, Carroll M, Melnick AM. Duy C, et al. Among authors: shih ah. Cancer Discov. 2019 Jul;9(7):872-889. doi: 10.1158/2159-8290.CD-19-0106. Epub 2019 May 10. Cancer Discov. 2019. PMID: 31076479 Free PMC article.
36 results